Core Insights - Cytokinetics is scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 [1] - The company is advancing a pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten, a cardiac myosin inhibitor, which is nearing regulatory approvals following positive Phase 3 trial results [3] - Cytokinetics is also developing other treatments such as omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy [3] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [3] - The company focuses on innovative treatments for patients suffering from diseases related to cardiac muscle dysfunction [3] - Aficamten is currently being evaluated in additional clinical trials for both obstructive and non-obstructive hypertrophic cardiomyopathy [3]
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum